Menlo Therapeutics Reports First Quarter 2018 Financial Results
“We continue to make progress on the serlopitant clinical development program. We have initiated the Phase 3 program in prurigo nodularis, our lead indication,” stated
First Quarter Business Highlights and Recent Developments
- In January, Menlo successfully completed an initial public offering (IPO) of 8,050,000 shares of common stock at a public offering price of
$17.00per share, which included the exercise in full by the underwriters of their overallotment option. The Company raised net proceeds of $125.4 millionafter deducting underwriting discounts, commissions and offering expenses.
- In April, Menlo announced
Japan Tobacco Inc.and Torii Pharmaceuticals Co. Ltd(together referred to as “JT Torii”), the Company’s partners for the development and commercialization of serlopitant in Japan, informed the Company that they have decided to halt the recently initiated Japanese Phase 2 clinical trial of serlopitant. JT Torii indicated that they are reevaluating their serlopitant development program based upon evolving commercial considerations in Japan. Based upon communication with JT Torii, the Company expects that the JT Torii license agreement for serlopitant will ultimately be terminated.
- In May, Menlo announced a realignment of roles with the promotion of a key member of the clinical development team.
Paul Kwon, M.D., a board-certified dermatologist, and Menlo’s Chief Medical Officer for the last two years will become Menlo’s Chief Scientific Officer. Dr. Kwon will be responsible for leading the scientific strategy of the serlopitant clinical program, exploring potential new indications and overseeing early stage clinical trials of serlopitant to support the anticipated new drug application. Mary Spellman, M.D., a board-certified dermatologist who has served as Menlo’s Senior Vice President, Clinical Development for the last year, will be promoted to Chief Medical Officer and will manage the planning and execution of late-stage clinical programs for serlopitant.
Clinical Program Updates
- In April, Menlo announced top-line results from the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis. The study did not meet its primary or key secondary efficacy endpoints with no statistically significant difference demonstrated between the serlopitant treated groups and the placebo treated group. Numerical differences favoring the serlopitant treated group were evident at all timepoints. Serlopitant was well-tolerated in this study.
- Menlo has initiated the first of two Phase 3 studies in pruritus associated with prurigo nodularis and will initiate the second study in the third quarter of 2018. The Company expects to enroll approximately 200 patients in each study. One study will be conducted in the U.S. and one in
- Menlo recently initiated a 52-week, multicenter, open-label safety study of serlopitant for the treatment of pruritus. The objective of this study is to provide long-term safety data for serlopitant in adults with pruritus associated with prurigo nodularis, atopic dermatitis, or psoriasis.
Refractory Chronic Cough
- Menlo expects to complete enrollment of more than 170 patients in a Phase 2 study in refractory chronic cough in
May 2018and to report top-line data in the fourth quarter of 2018 as previously indicated.
- Menlo’s Phase 2 study in pruritus associated with psoriasis is greater than 60% enrolled, and the Company expects to report top-line data in late 2018 or early 2019 as previously indicated.
First Quarter 2018 Financial Results
Menlo reported a net loss attributable to common stockholders of $12.7 million for the first quarter of 2018, compared to a net loss of $5.5 million for the same period in 2017.
Collaboration and license revenue was
Research and development expenses were $11.0 million in the first quarter of 2018, compared to $5.0 million for the same period in 2017. The increase was primarily due to an increase in clinical trial expenses related to the development of serlopitant and higher personnel-related expenses.
General and administrative expenses were $2.7 million in the first quarter of 2018, compared to $1.0 million for the same period in 2017. The increase was primarily due to higher personnel-related expenses to support the Company’s expanding operations.
As of March 31, 2018, Menlo had $176.6 million in cash, cash equivalents and investments, compared to $62.5 million as of December 31, 2017. In
Menlo is lowering its operating expense guidance for the full year 2018 to a range of approximately
Forward Looking Statements
This press release contains forward-looking statements, including but not limited to the potential of serlopitant to treat pruritus associated with psoriasis and prurigo nodularis, or to treat refractory chronic cough, the conduct and anticipated announcement of results of Phase 2 clinical studies for pruritus associated with psoriasis and for refractory chronic cough, expectations about the start and conduct of Phase 3 clinical trials for pruritus associated with prurigo nodularis, objectives for the multicenter, open-label safety study of serlopitant for the treatment of pruritus, the expectation that the JT Torii license for serlopitant will ultimately be terminated, and expected operating expenses for the full year 2018. Such forward-looking statements involve substantial risk and uncertainties that could cause Menlo Therapeutics’ development program for serlopitant, future results, achievements or performance to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks that the timing of enrollment or commencement of clinical trials may be delayed, the risk that subsequent trials do not replicate the results from completed clinical trials or do not demonstrate efficacy of serlopitant in the studied indications, the risk of adverse safety events, risks that the costs of clinical trials will exceed expectations, risks that
- See attached financial tables –
|Menlo Therapeutics Inc.|
|Condensed Statements of Operations|
|(In thousands, except per share data, unaudited)|
|Three Months Ended|
|Collaboration and license revenue||$||497||$||449|
|Research and development||11,020||4,992|
|General and administrative||2,697||1,012|
|Loss from operations||(13,220||)||(5,555||)|
|Interest income and other expense, net||563||81|
|Net loss per share attributable to common stockholders, basic and
|Weighted average common shares used to compute net loss per
share attributable to common stockholders, basic and diluted
|Menlo Therapeutics Inc.|
|Condensed Balance Sheet Data|
|March 31,||December 31,|
|Cash, cash equivalents and investments||$||176,550||$||62,479|
|Stockholders' equity (deficit)||165,702||(57,034||)|
- Derived from the audited financial statements, included in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2017.
Media Contact: email@example.com
Investor Contact: firstname.lastname@example.org
Source: Menlo Therapeutics Inc.